Logo image of THTX

THERATECHNOLOGIES INC (THTX) Stock Fundamental Analysis

NASDAQ:THTX - CA88338H7040 - Common Stock

3.24 USD
-0.01 (-0.31%)
Last: 8/29/2025, 8:00:01 PM
Fundamental Rating

3

Overall THTX gets a fundamental rating of 3 out of 10. We evaluated THTX against 542 industry peers in the Biotechnology industry. THTX has a medium profitability rating, but doesn't score so well on its financial health evaluation. THTX is valued correctly, but it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

4

1. Profitability

1.1 Basic Checks

THTX had negative earnings in the past year.
THTX had a positive operating cash flow in the past year.
THTX had negative earnings in each of the past 5 years.
THTX had negative operating cash flow in 4 of the past 5 years.
THTX Yearly Net Income VS EBIT VS OCF VS FCFTHTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10M -20M -30M -40M

1.2 Ratios

Looking at the Return On Assets, with a value of -17.86%, THTX is in the better half of the industry, outperforming 79.23% of the companies in the same industry.
Looking at the Return On Invested Capital, with a value of 55.37%, THTX belongs to the top of the industry, outperforming 99.45% of the companies in the same industry.
Industry RankSector Rank
ROA -17.86%
ROE N/A
ROIC 55.37%
ROA(3y)-32.34%
ROA(5y)-29.26%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
THTX Yearly ROA, ROE, ROICTHTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 -400 -600

1.3 Margins

THTX has a better Operating Margin (10.05%) than 92.46% of its industry peers.
THTX's Gross Margin of 77.72% is amongst the best of the industry. THTX outperforms 83.82% of its industry peers.
THTX's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 10.05%
PM (TTM) N/A
GM 77.72%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.54%
GM growth 5Y5.34%
THTX Yearly Profit, Operating, Gross MarginsTHTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50

More info and screens

1

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so THTX is creating value.
THTX has about the same amout of shares outstanding than it did 1 year ago.
The number of shares outstanding for THTX has been reduced compared to 5 years ago.
The debt/assets ratio for THTX is higher compared to a year ago.
THTX Yearly Shares OutstandingTHTX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
THTX Yearly Total Debt VS Total AssetsTHTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

THTX has an Altman-Z score of -8.33. This is a bad value and indicates that THTX is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -8.33, THTX is not doing good in the industry: 68.93% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -8.33
ROIC/WACC4.74
WACC11.67%
THTX Yearly LT Debt VS Equity VS FCFTHTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M

2.3 Liquidity

A Current Ratio of 0.84 indicates that THTX may have some problems paying its short term obligations.
THTX has a worse Current ratio (0.84) than 89.34% of its industry peers.
THTX has a Quick Ratio of 0.84. This is a bad value and indicates that THTX is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 0.65, THTX is doing worse than 91.18% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.84
Quick Ratio 0.65
THTX Yearly Current Assets VS Current LiabilitesTHTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

3

3. Growth

3.1 Past

The earnings per share for THTX have decreased by 0.00% in the last year.
The Revenue has been growing slightly by 2.19% in the past year.
Measured over the past years, THTX shows a small growth in Revenue. The Revenue has been growing by 6.31% on average per year.
EPS 1Y (TTM)0%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-550%
Revenue 1Y (TTM)2.19%
Revenue growth 3Y7.14%
Revenue growth 5Y6.31%
Sales Q2Q%-19.48%

3.2 Future

Based on estimates for the next years, THTX will show a very strong growth in Earnings Per Share. The EPS will grow by 29.71% on average per year.
THTX is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 6.64% yearly.
EPS Next Y88.56%
EPS Next 2Y66.79%
EPS Next 3Y46.8%
EPS Next 5Y29.71%
Revenue Next Year-3.03%
Revenue Next 2Y5.03%
Revenue Next 3Y5.76%
Revenue Next 5Y6.64%

3.3 Evolution

The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
THTX Yearly Revenue VS EstimatesTHTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 50M 100M 150M
THTX Yearly EPS VS EstimatesTHTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 1 -1 2 3

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for THTX. In the last year negative earnings were reported.
Based on the Price/Forward Earnings ratio of 23.02, the valuation of THTX can be described as rather expensive.
Based on the Price/Forward Earnings ratio, THTX is valued cheaper than 92.10% of the companies in the same industry.
THTX is valuated at similar levels of the S&P average when we compare the Price/Forward Earnings ratio to 22.76, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 23.02
THTX Price Earnings VS Forward Price EarningsTHTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

THTX's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. THTX is cheaper than 93.75% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 17.52
THTX Per share dataTHTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 1.5

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as THTX's earnings are expected to grow with 46.80% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y66.79%
EPS Next 3Y46.8%

More info and screens

0

5. Dividend

5.1 Amount

THTX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

THERATECHNOLOGIES INC

NASDAQ:THTX (8/29/2025, 8:00:01 PM)

3.24

-0.01 (-0.31%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)07-09 2025-07-09/bmo
Earnings (Next)10-08 2025-10-08/bmo
Inst Owners24.06%
Inst Owner Change-5.42%
Ins Owners0.91%
Ins Owner ChangeN/A
Market Cap148.98M
Analysts84
Price Target4.06 (25.31%)
Short Float %0.66%
Short Ratio0.4
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-291.26%
Min EPS beat(2)-482.52%
Max EPS beat(2)-100%
EPS beat(4)1
Avg EPS beat(4)-224.76%
Min EPS beat(4)-482.52%
Max EPS beat(4)94.17%
EPS beat(8)5
Avg EPS beat(8)-62.95%
EPS beat(12)6
Avg EPS beat(12)-46.18%
EPS beat(16)6
Avg EPS beat(16)-49.02%
Revenue beat(2)0
Avg Revenue beat(2)-5.7%
Min Revenue beat(2)-9.5%
Max Revenue beat(2)-1.91%
Revenue beat(4)1
Avg Revenue beat(4)-3.24%
Min Revenue beat(4)-9.5%
Max Revenue beat(4)6.97%
Revenue beat(8)1
Avg Revenue beat(8)-5.3%
Revenue beat(12)1
Avg Revenue beat(12)-6.15%
Revenue beat(16)1
Avg Revenue beat(16)-7.55%
PT rev (1m)-1.02%
PT rev (3m)0.33%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-62.5%
EPS NY rev (1m)-124%
EPS NY rev (3m)-124%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-2.63%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.08%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 23.02
P/S 1.77
P/FCF N/A
P/OCF 21.17
P/B N/A
P/tB N/A
EV/EBITDA 17.52
EPS(TTM)-0.19
EYN/A
EPS(NY)0.14
Fwd EY4.34%
FCF(TTM)-0.07
FCFYN/A
OCF(TTM)0.15
OCFY4.72%
SpS1.84
BVpS-0.61
TBVpS-0.98
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -17.86%
ROE N/A
ROCE 70.09%
ROIC 55.37%
ROICexc 307.38%
ROICexgc N/A
OM 10.05%
PM (TTM) N/A
GM 77.72%
FCFM N/A
ROA(3y)-32.34%
ROA(5y)-29.26%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.54%
GM growth 5Y5.34%
F-Score4
Asset Turnover1.65
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA 3.84
Cap/Depr 519.63%
Cap/Sales 11.98%
Interest Coverage 1.21
Cash Conversion 67.47%
Profit Quality N/A
Current Ratio 0.84
Quick Ratio 0.65
Altman-Z -8.33
F-Score4
WACC11.67%
ROIC/WACC4.74
Cap/Depr(3y)39.02%
Cap/Depr(5y)23.86%
Cap/Sales(3y)1.73%
Cap/Sales(5y)1.1%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)0%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-550%
EPS Next Y88.56%
EPS Next 2Y66.79%
EPS Next 3Y46.8%
EPS Next 5Y29.71%
Revenue 1Y (TTM)2.19%
Revenue growth 3Y7.14%
Revenue growth 5Y6.31%
Sales Q2Q%-19.48%
Revenue Next Year-3.03%
Revenue Next 2Y5.03%
Revenue Next 3Y5.76%
Revenue Next 5Y6.64%
EBIT growth 1Y125.23%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year4.1%
EBIT Next 3Y43.2%
EBIT Next 5Y34.29%
FCF growth 1Y82.2%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y143.06%
OCF growth 3YN/A
OCF growth 5YN/A